First published 9/29/2026, 2:45:15 AM · Last updated 9/29/2026, 2:45:15 AM

Symmetrical Drug‐Related Intertriginous and Flexural Exanthema ( <scp>SDRIFE</scp> ) due to Dexamethasone Used as Oncologic Premedication

A Wiley journal article reports a case of symmetrical drug-related intertriginous and flexural exanthema attributed to dexamethasone given as premedication in oncology. The supplied source fields include only publisher, content type, DOI, and publication date with no additional clinical details.

Categories: public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 2/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 2/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 2/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The article documents an adverse skin reaction associated with dexamethasone used in oncologic premedication.

Sources

Symmetrical Drug‐Related Intertriginous and Flexural Exanthema ( <scp>SDRIFE</scp> ) due to Dexamethasone Used as Oncologic Premedication

Report an issue